Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Cellectis announces a strategic transformation to become an in vivo gene editing company, advancing two lead gene editing programs, .HEAL-101 and .HEAL-201, targeting severe hypertriglyceridemia and severe hypercholesterolemia respectively. The company plans to initiate Phase 1 trials and share preliminary data by 2027-2028, while exiting developme…